Table 1.
Elite Controller Study Population Characteristics.
| Subject ID | Gender1 | Age2 | CD43 | CD83 | Duration of infection2 | %CD38+DR+CD8+ | Duration CD4 FUP/VL control2,3 | #CD4 assessments | Annual Rate of CD4 decline4 |
|---|---|---|---|---|---|---|---|---|---|
| EC 1 | M | 37 | 680 | 680 | 1 | 14.60 | 2.91 | 8 | 9.4 (-55.9,74.8) |
| EC 2 | M | 31 | 715 | 384 | 5 | 5.42 | 5.14 | 11 | -17.7 (-56.2,20.8) |
| EC 3 | M | 68 | 660 | 1082 | 4 | 3.59 | 5.16 | 17 | 6.19 (-14.5,26.7) |
| EC 4 | F | 58 | 714 | 714 | 4 | 4.68 | 5.77 | 14 | -6.73 (-50.7,37.2) |
| EC 5 | M | 53 | 310 | 730 | 6 | 3.95 | 5.27 | 14 | -52.6 (-76.6,28.5) |
| EC 6 | F | 46 | 720 | 631 | 11 | 6.63 | 8.75 | 25 | -7.4 (-22.7,8.0) |
| EC 7 | M | 37 | 1040 | 1095 | 11 | 4.33 | 9.64 | 22 | 14.4 (-6.5,35.3) |
| EC 8 | F | 40 | 737 | 303 | 12 | 7.11 | 12.08/14.52 | 22 | -44.2 (-58.0,-30,4) |
| EC 9 | M | 53 | 800 | 288 | 10 | 7.35 | 14.88 | 35 | 15.9 (10.3,21.6) |
| EC 10 | M | 45 | 1050 | 1296 | 20 | 7.41 | 12.27 | 22 | -11.2 (-27.9,5.4) |
| EC 11 | M | 39 | 689 | 455 | 9 | 10.20 | 16.78/9.12 | 86 | -48.9 (-59.2,-38.6) |
| EC 12 | F | 33 | 728 | 434 | 10 | 2.36 | 17.30 | 79 | -49.2 (-53.4,-45.0) |
| EC 13 | M | 47 | 770 | 1130 | 19 | 12.70 | 20.02/21.63 | 17 | -33.0 (-50.6,-15.3) |
| EC 14 | M | 31 | 928 | 1566 | 2 | 20.00 | 2.75 | N.A. | N.A.5 |
| EC 15 | F | 31 | 442 | 816 | 2 | 12.40 | 4.75 | 4 | 15.8 (-19.3,50.9) |
| EC 16 | F | 60 | 800 | 1026 | 13 | 3.00 | 13.64 | 8 | -5.3 (-58,7,58.0) |
| EC 17 | M | 40 | 460 | 307 | 4 | 6.35 | 3.87 | 10 | 4.3 (-40.9,49.6) |
| EC 18 | M | 42 | 870 | 551 | 1 | 8.27 | 1.50 | N.A. | N.A. |
| EC 19 | F | 30 | 692 | 627 | 6 | 10.10 | 2.17 | 6 | -17.0 (-121.5,87.5) |
| EC 20 | F | 40 | 576 | 498 | 12 | 20.20 | 15.18/15.73 | 13 | -30.9 (-50.2,-11.7) |
| EC 21 | M | 36 | 343 | 804 | 14 | 12.20 | 1.05 | N.A. | N.A. |
| EC 22 | M | 61 | 670 | 540 | 4 | 12.5 | 4.62 | 11 | 32.1 (-27.3,91.5) |
| EC 23 | M | 53 | 740 | 820 | 11 | 33.2 | 18.01 | 16 | -15.1 (-33.3,3.0) |
| EC 24 | M | 41 | 978 | 787 | 1 | 37.3 | 11.24 | 29 | -16.0 (-27.6,-4.4) |
| EC 25 | M | 55 | 990 | 680 | 10 | 15.3 | 9.48 | 16 | -29.0 (-70.5, 12.5) |
| EC 26 | M | 68 | 970 | 400 | 17 | 17.5 | 13.18 | 19 | 14.5 (3.8,25.2) |
| EC 27 | M | 41 | 1200 | 860 | 11 | 13.9 | 12.39 | 34 | 28.6 (7.4,49.7) |
| EC 28 | M | 48 | 700 | 920 | 8 | 35.4 | 17.20 | 35 | -1.4 (-5.0,2.1) |
| EC 29 | F | 53 | 499 | 202 | 8 | 28.9 | N.A. | N.A. | N.A. |
| EC 30 | M | 40 | 510 | 1286 | 14 | 21.5 | N.A. | N.A. | N.A. |
| EC 31 | F | 47 | 485 | 277 | 20 | 17.3 | N.A. | N.A. | N.A. |
| EC 32 | F | 56 | 865 | 388 | 15 | 20.7 | N.A. | N.A. | N.A. |
| EC 33 | F | 56 | 1488 | 1012 | 17 | 2.39 | N.A. | N.A. | N.A. |
| EC 34 | M | 56 | 801 | 713 | 18 | 20.7 | N.A. | N.A. | N.A. |
1M = male;F = female
2 years.
3The duration of CD4 follow up/duration of viral load control if different from duration of CD4 follow up.
4 cells/mm3 (95% confidence intervals).
5 Not available (insufficient information available to calculate a slope of CD4 counts change).